100,000 Genomes Pilot on Rare-Disease Diagnosis in Health Care — Preliminary Report

Abstract

Background The UK 100,000 Genomes Project is in the process of investigating the role of genome sequencing of patients with undiagnosed rare disease following usual care, and the alignment of research with healthcare implementation in the UK’s national health service. (Other parts of this Project focus on patients with cancer and infection.) Methods We enrolled participants, collected clinical features with human phenotype ontology terms, undertook genome sequencing and applied automated variant prioritization based on virtual gene panels (PanelApp) and phenotypes (Exomiser), alongside identification of novel pathogenic variants through research analysis. We report results on a pilot study of 4660 participants from 2183 families with 161 disorders covering a broad spectrum of rare disease. Results Diagnostic yields varied by family structure and were highest in trios and larger pedigrees. Likely monogenic disorders had much higher diagnostic yields (35%) with intellectual disability, hearing and vision disorders, achieving yields between 40 and 55%. Those with more complex etiologies had an overall 25% yield. Combining research and automated approaches was critical to 14% of diagnoses in which we found etiologic non-coding, structural and mitochondrial genome variants and coding variants poorly covered by exome sequencing. Cohort-wide burden testing across 57,000 genomes enabled discovery of 3 new disease genes and 19 novel associations. Of the genetic diagnoses that we made, 24% had immediate ramifications for the clinical decision-making for the patient or their relatives. Conclusion Our pilot study of genome sequencing in a national health care system demonstrates diagnostic uplift across a range of rare diseases. (Funded by National Institute for Health Research and others)

GREEN-DB: a framework for the annotation and prioritization of non-coding regulatory variants from whole-genome sequencing data

“…The increasing adoption of whole-genome (WGS) over whole-exome (WES) sequencing in disease studies now allows for the comprehensive investigation of human variants ( 41 ), including those affecting these regulatory regions. The accurate identification, interpretation and prioritization of such WGS-derived variants requires standardized resources for their annotation in routine bioinformatics pipelines in order to identify likely pathogenic regulatory variants.…”

RNA sequencing role and application in clinical diagnostic

“…2 While whole-genome sequencing (WGS) provides comprehensive information on the 3 billion bases of the human DNA, the diagnostic yield over WES improves by only 5% (Figure 1). 3 This DOI: 10.1002/ped4.12314…”

Exploring Rare Disease Patient Attitudes and Beliefs regarding Genetic Testing: Implications for Person-Centered Care

“…Such diagnostic delays can cause significant psychological, emotional, and financial distress as well as delays in initiating care and treatment. As most rare diseases are genetic in etiology, the growth of next-generation sequencing offers new avenues to accelerate diagnosis for rare diseases [ 3 , 4 ].…”